MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Pharmaceutical Executive
July 3, 2007
Jill Wechsler
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. mark for My Articles similar articles
Knowledge@Wharton Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2006
Joanna Breitstein
Breath of Hope: TB in Africa For the first time in decades, the pharmaceutical industry has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem. mark for My Articles similar articles
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2011
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? mark for My Articles similar articles
Chemistry World
November 1, 2011
Sarah Houlton
A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases. mark for My Articles similar articles
Chemistry World
September 11, 2012
Maria Burke
Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2012
Carol Ann Williams
Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2006
Kieran Hartsough
Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside. mark for My Articles similar articles
BusinessWeek
October 18, 2004
Catherine Arnst
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2010
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
Jill Wechsler
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2014
Jill Wechsler
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2011
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. mark for My Articles similar articles
Pharmaceutical Executive
July 3, 2007
Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work. mark for My Articles similar articles
The Motley Fool
June 28, 2010
Luke Timmerman
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. mark for My Articles similar articles
HBS Working Knowledge
February 28, 2005
Cynthia Churchwell
Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution. mark for My Articles similar articles
BusinessWeek
April 26, 2004
Kerry Capell
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. mark for My Articles similar articles
Chemistry World
March 27, 2013
Eugene Gerden
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. mark for My Articles similar articles
The Motley Fool
September 9, 2004
Charly Travers
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. mark for My Articles similar articles
Chemistry World
August 23, 2012
Simon Campbell
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. mark for My Articles similar articles
BusinessWeek
April 18, 2005
Manjeet Kripalani
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. mark for My Articles similar articles
Chemistry World
May 31, 2013
Phillip Broadwith
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. mark for My Articles similar articles
The Motley Fool
January 21, 2010
Brian Orelli
The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments. mark for My Articles similar articles
BusinessWeek
November 29, 2004
Catherine Arnst
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. mark for My Articles similar articles
Pharmaceutical Executive
July 3, 2007
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2013
William Looney
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
Zhu Shen
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2013
Jill Wechsler
Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2010
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2011
Jill Wechsler
At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system. mark for My Articles similar articles
The Motley Fool
May 21, 2010
Brian Orelli
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. mark for My Articles similar articles
Pharmaceutical Executive
July 10, 2014
William Looney
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2011
Ben Comer
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2014
Jill Wechsler
Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge. mark for My Articles similar articles
The Motley Fool
November 30, 2010
Brian Orelli
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2012
Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2006
Ron Feemster
Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials. mark for My Articles similar articles
Chemistry World
December 17, 2015
Sarah Houlton
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2007
Walter Armstrong
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2013
Jill Wechsler
Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise. mark for My Articles similar articles
Chemistry World
December 15, 2009
Sarah Houlton
Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2007
Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge. mark for My Articles similar articles
Chemistry World
September 10, 2015
Katrina Megget
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions mark for My Articles similar articles
The Motley Fool
December 28, 2004
Charly Travers
It's All in the Delivery If too much risk makes you queasy, these drug companies are for you. SkyePharma... DepoMed... mark for My Articles similar articles
BusinessWeek
April 19, 2004
John Carey
Drugs: Is Something Rotten? The author of The $800 million pill recounts how many drugs were created with government funding -- then were sold to consumers at sky-high prices. And he proves that Big Pharma need not require $800 million to develop an important new drug, as it insists. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Brad Miles
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs mark for My Articles similar articles